Ark Therapeutics Group plc is engaged in the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. The Company�s business activity includes the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The products in the Company focuses to partner with include Neuropilin-1 antagonists for anti-tumour therapy; EG011 for refractory angina; EG013 for fetal growth restriction; EG016 for peripheral vascular disease; Cerepro for malignant glioma, and Trinam for maintaining vascular access grafts. Ark Therapeutics Oy is the Company�s subsidiary, which is engaged the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. The Company conducts research at its facilities in Kuopio Finland, at University College London.